AR027352A1 - Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos - Google Patents

Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos

Info

Publication number
AR027352A1
AR027352A1 ARP010100494A ARP010100494A AR027352A1 AR 027352 A1 AR027352 A1 AR 027352A1 AR P010100494 A ARP010100494 A AR P010100494A AR P010100494 A ARP010100494 A AR P010100494A AR 027352 A1 AR027352 A1 AR 027352A1
Authority
AR
Argentina
Prior art keywords
alkyl
well
so2h
nr7r8
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP010100494A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR027352A1 publication Critical patent/AR027352A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP010100494A 2000-02-02 2001-02-02 Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos Suspension/Interruption AR027352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10004572A DE10004572A1 (de) 2000-02-02 2000-02-02 Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR027352A1 true AR027352A1 (es) 2003-03-26

Family

ID=7629599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100494A Suspension/Interruption AR027352A1 (es) 2000-02-02 2001-02-02 Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos

Country Status (16)

Country Link
US (3) US6525045B2 (xx)
EP (1) EP1265904B1 (xx)
JP (1) JP4891510B2 (xx)
AR (1) AR027352A1 (xx)
AT (1) ATE277054T1 (xx)
AU (1) AU2001240561A1 (xx)
CA (1) CA2399377C (xx)
CO (1) CO5261505A1 (xx)
DE (2) DE10004572A1 (xx)
DK (1) DK1265904T3 (xx)
ES (1) ES2228817T3 (xx)
MX (1) MXPA02007460A (xx)
PT (1) PT1265904E (xx)
TR (1) TR200402650T4 (xx)
UY (1) UY26566A1 (xx)
WO (1) WO2001057045A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
NZ520588A (en) * 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
KR100982753B1 (ko) * 2001-04-05 2010-09-16 콜라제넥스 파마슈티칼스, 인크 테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절
US20030100552A1 (en) 2001-05-17 2003-05-29 Boehringer Ingelheim Pharma Kg Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions
DE10123952A1 (de) * 2001-05-17 2002-11-21 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2458388A1 (en) * 2001-10-10 2003-04-17 Neurosearch A/S Novel benzothiazine derivatives, their preparation and use
US7815391B2 (en) * 2004-07-23 2010-10-19 Kauppila Richard W Structural member joints
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
AU2009243730B2 (en) * 2008-05-05 2013-07-18 Polypeptide Laboratories Holding (Ppl) Ab Indolesulfonyl protecting groups for protection of guanidino and amino groups
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724566D0 (en) * 1987-10-20 1987-11-25 Roussel Lab Ltd Chemical compounds
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
AU3957093A (en) * 1992-04-15 1993-11-18 Rhone-Poulenc Rorer S.A. 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxyl ic acid derivatives, preparation thereof and drugs containing same
ES2149989T3 (es) * 1994-05-24 2000-11-16 Hoffmann La Roche Derivados triciclicos de dicarbonilo.
US5891871A (en) * 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
WO1998012185A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
US5968928A (en) * 1996-09-19 1999-10-19 Warner-Lambert Company Excitatory amino acid antagonists: fused-azacyclic quinoxalinediones and immunoassays thereof
US5969138A (en) * 1996-11-01 1999-10-19 Mitsui Chemicals, Inc. Pyrrolidinone derivatives
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
ZA991301B (en) * 1998-02-18 1999-09-13 Neurosearch As Glutamate receptor modulators.
US6096744A (en) * 1998-05-04 2000-08-01 Warner-Lambert Company Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2399377C (en) 2008-12-16
MXPA02007460A (es) 2003-01-28
US20030158181A1 (en) 2003-08-21
US20030158183A1 (en) 2003-08-21
TR200402650T4 (tr) 2004-11-22
ES2228817T3 (es) 2005-04-16
US6800623B2 (en) 2004-10-05
PT1265904E (pt) 2004-11-30
DE10004572A1 (de) 2001-08-09
JP2003522180A (ja) 2003-07-22
DE50103760D1 (de) 2004-10-28
UY26566A1 (es) 2001-08-27
WO2001057045A1 (de) 2001-08-09
EP1265904A1 (de) 2002-12-18
EP1265904B1 (de) 2004-09-22
CO5261505A1 (es) 2003-03-31
DK1265904T3 (da) 2004-10-25
ATE277054T1 (de) 2004-10-15
US20020013313A1 (en) 2002-01-31
JP4891510B2 (ja) 2012-03-07
AU2001240561A1 (en) 2001-08-14
CA2399377A1 (en) 2001-08-09
US6525045B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
SV2008002828A (es) Agentes para prevenir y tratar trastornos que involucran la modulacion de los receptores ryr ref. 19240-619-sv1
AR027352A1 (es) Nuevos moduladores alostericos positivos de receptores de ampa (paarm), procedimientos para su preparacion y su utilizacion como medicamentos
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
CY1110392T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR053235A1 (es) Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
AR049483A1 (es) Combinacion de herbicidas
UY34112A (es) Composiciones farmacéuticas que contienen un agente neuroléptico y un inhibidor sglt2 y usos de los mismos
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR063027A1 (es) Derivados de sulfonamida
AR057887A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
AR066873A1 (es) Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
AR047486A1 (es) Derivados de indolizina1,2,3,6,7,8, substituida, inhibidores de los fgfs, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR085236A1 (es) Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos
AR069781A1 (es) Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia.
EA202190245A1 (ru) Производные спирохромана

Legal Events

Date Code Title Description
FB Suspension of granting procedure